WORC.COMMUNITY · LEARN THE FOUNDATIONS

Your introductory guide to Advanced Cell Models

Understand the models. Learn the language. Explore the science.

From organoids and spheroids to organ-on-a-chip and engineered tissues, discover how researchers model selected aspects of biology outside the body.

Community. Connections. Collaboration. · #BetterTogether

Start here: what makes a model “advanced”?

Advanced cell models add biological organisation or control beyond a basic cell monolayer: multiple cell types, tissue-like structures, extracellular matrix, fluid flow, mechanical cues or combinations of these. The aim is to capture the biology needed to answer a specific question.

A model represents selected features of biology. An organoid is not a complete miniature organ, and a chip does not reproduce every function of the body. A more complex model is useful when that complexity improves the answer.

Three overlapping ideas

3D describes spatial arrangement. Microphysiological systems (MPS) describe models of tissue or organ physiology. New approach methodologies (NAMs) describe approaches to replacing animal testing, particularly in safety assessment. These terms overlap but are not interchangeable.

A simple learning route

  1. Watch Hans Clevers’s disease-modelling lecture and the chip webinar at the top of the page.
  2. Read the definitions here, then explore the model families.
  3. Compare the features your question needs.
  4. Use the glossary whenever a term is unfamiliar.

Watch & learn

Watch the disease-modelling lecture or the beginner chip webinar, then read Start here for definitions and the model guide. Videos are credited to their original providers.

iBiology · Hans Clevers · Part 3 · 32:13

Organoid Technology for Disease Modeling

Examples of disease modelling and patient-specific response studies.

Watch at source ↗

Players load only when selected and connect to YouTube. If playback is unavailable or an embed is blocked, use “Watch at source”. The iBiology lecture was recorded in September 2019; it provides foundational teaching rather than a current regulatory overview.

Build capability

Training & practical resources

Courses, summer schools, webinars, culture guides and tailored support for adopting and using advanced models.

Upcoming training calendar

Calendar reviewed 9 November 2026. Completed events are hidden automatically after their final day. Dates and access are checked against provider sources during scheduled reviews; confirm eligibility, deadlines and remaining places before booking.

Training links are separate from the organisation directory filters. Dated, archived and consortium-only activities are labelled; a listing does not imply that enrolment is open. Online includes recorded webinars, virtual courses and digital practical resources. A provider with both badges has separate online and in-person options; this does not imply a hybrid course. Check the provider for dates, access and fees.

Meet the model families

Use the comparison below for definitions, applications, strengths and limitations. These cards highlight questions to ask when choosing or evaluating a model.

MODEL FAMILY / APPROACH

Spheroids

Start with the geometry: Will aggregate size and compactness affect your readout? Record both when comparing cultures.

MODEL FAMILY / APPROACH

Organoids

Look for tissue identity: Which tissue features must be present? Choose identity and function checks before interpreting the model.

MODEL FAMILY / APPROACH

Patient-derived organoids / tumoroids

Track the sample: Does the culture represent the original sample? Keep donor, sampling and passage information linked to the readout.

MODEL FAMILY / APPROACH

Vascularised organoids

Check vessel function: Do you need vascular cells, vessel structure or actual perfusion? Define which of these your experiment tests.

MODEL FAMILY / APPROACH

Assembloids

Test the connection: What interaction should joining components reveal? Include a way to measure that interaction.

MODEL FAMILY / APPROACH

Bioprinted tissues

Design around the endpoint: Which spatial arrangement matters for your question? Assess whether the printed tissue retains the required biology.

MODEL FAMILY / APPROACH

Advanced 2D & barrier models

Choose the exposed surface: Which compartment receives treatment, and where will you measure transport or barrier function?

MODEL FAMILY / APPROACH

Organ-on-a-chip

Plan the device controls: How could flow, device materials or the exposure setup change your measurement? Include appropriate controls.

MODEL FAMILY / APPROACH

Organoid-on-a-chip

Separate tissue and device effects: What does the chip add to the organoid? Compare against a suitable organoid-only condition where practical.

MODEL FAMILY / APPROACH

Linked multi-organ systems

Define the link: Which signal or metabolite should travel between tissues? Check that the coupling supports that question.

MODEL FAMILY / APPROACH

Organotypic cultures & tissue slices

Consider the observation window: How long must native tissue features remain stable for your endpoint? Account for handling and time in culture.

MODEL FAMILY / APPROACH

Microphysiological systems (MPS)

Specify the physiology: Which tissue function is the platform intended to reproduce? Describe that function rather than relying on the MPS label.

Comparison of key advanced cell models

These approaches overlap and can be combined. There is no universal ranking from simplest to most complex: choose the features needed for your research question. Advantages and limitations depend on the specific implementation. Patient-derived and vascularised organoids are overlapping variants; MPS is an umbrella term rather than an additional step in complexity.

Model type Definition & structure Potential advantages Key limitations Typical uses Quick glance
Spheroids 3D cell aggregates containing one or several cell types; some develop internal organisation. Often compatible with parallel screening; relatively straightforward formation in many protocols. Size and composition can vary; diffusion gradients and core necrosis may develop; tissue architecture is model-dependent. Drug screening, tumour biology, drug penetration and cell interactions. Throughput: High
Cost: Low–medium
Complexity: Low–medium
Organoids Self-organising 3D cultures reproducing selected tissue architecture and function, derived from stem, progenitor or differentiated cells. Tissue-specific organisation; donor-derived cultures can retain relevant genetic and disease features. Variable maturity and composition; missing tissue components; matrix and batch effects; diffusion limits in larger structures. Development, disease mechanisms, drug response and precision medicine research. Throughput: Medium
Cost: Medium–high
Complexity: Medium–high
Patient-derived organoids / tumoroids Organoids established from patient samples; tumour-derived organoids are often called tumoroids. Patient-derived cultures can also come from non-cancerous tissue. Can retain relevant donor-specific molecular and tissue features; suitable cultures can be expanded and biobanked. Establishment success, time and representation vary; sampling and culture selection can alter heterogeneity; immune and stromal components may be absent. Patient-specific disease research, functional drug testing and biobanks; treatment guidance requires application-specific clinical evidence. Throughput: Low–medium during establishment; higher after expansion
Cost: Medium–high
Complexity: Medium–high
Vascularised organoids Organoids containing or integrated with vascular structures, generated through differentiation, co-culture or other engineering approaches. Can model tissue–vascular interactions; demonstrated functional perfusion can improve transport and support tissue development. Vascular markers or vessel-like structures do not establish a functional blood supply; perfusion, maturity and consistency need verification. Angiogenesis, vascular interactions, development and perfusion-dependent biology. Throughput: Low–medium
Cost: High
Complexity: High
Assembloids Integrated systems combining organoids with other organoids or specialised cell populations. Enables study of interactions, migration and functional connections between components. Variable integration and maturation; connections need verification; flow requires additional engineering. Neural circuits, neuromuscular interactions and communication between tissue components. Throughput: Low–medium
Cost: High
Complexity: High
Bioprinted tissues Cells and biomaterials deposited in a designed spatial arrangement. Control of geometry and cell placement; reproducible fabrication is possible with optimised processes. Printing stress, bioink constraints, maturation and nutrient delivery; fabrication consistency does not guarantee biological consistency. Engineered tissue architecture, organised co-culture and disease models. Throughput: Low–medium; automation can increase it
Cost: Medium–high
Complexity: High
Advanced 2D & barrier models Polarised monolayers or co-cultures, including Transwell and air–liquid interface systems. Accessible barrier and transport readouts; compartment control; scalability in many formats. Limited tissue depth and systemic context; differentiation and barrier quality require confirmation. Airway biology, permeability, transport and epithelial or endothelial barriers. Throughput: Medium–high
Cost: Low–medium
Complexity: Low–medium
Organ-on-a-chip Engineered devices containing living cell layers, 3D tissues or organoids, with controlled microenvironmental cues. Control of interfaces, exposure and often flow; some designs provide mechanical stimulation. Material–compound interactions, bubbles and technical demands; complexity and throughput vary. Barrier function, transport, mechanobiology, exposure-response and toxicity studies. Throughput: Low–medium; parallel formats available
Cost: Medium–high
Complexity: Medium–high
Organoid-on-a-chip An organoid integrated into a chip-based culture system. Combines self-organised tissue features with control of flow, nutrient delivery or exposure. Integration adds technical demands; external perfusion does not guarantee internal vascularisation, maturity or prevention of necrosis. Dynamic disease models, exposure studies and longer-term culture where performance is demonstrated. Throughput: Low–medium
Cost: High
Complexity: High
Linked multi-organ systems Two or more tissue models connected through shared or transferred culture medium. Studies of inter-tissue signalling and metabolism-dependent effects. Compatible media, tissue scaling, residence times and interpretation are challenging; does not reproduce the whole body. Inter-organ communication, metabolism-linked toxicity and selected pharmacokinetic questions. Throughput: Low
Cost: High
Complexity: High
Organotypic cultures & tissue slices Cultures with tissue-like organisation; slices retain part of an existing tissue’s native architecture. Preserved local cell diversity and interactions, particularly in freshly prepared slices. Tissue access, donor variation, cut-surface injury and limited culture lifespan. Local tissue responses, multicellular mechanisms and short-term treatment studies. Throughput: Low–medium
Cost: Medium–high
Complexity: Medium–high
Microphysiological systems (MPS) An umbrella term for in vitro platforms modelling selected tissue or organ physiology; broader definitions include several model families shown here. Integrates relevant cellular organisation and environmental cues for a defined function. Definitions vary; physiology and predictive performance require evidence for the intended use. Mechanistic research, disease models and application-specific safety assessment. Throughput: Varies by platform
Cost: Varies by platform
Complexity: Varies by platform

Quick-glance estimates: These are editorial, qualitative starting points, not measured scores or price quotes. Throughput means parallel experimental capacity; cost includes culture and platform resources; complexity includes setup and operation. Ratings overlap and vary with tissue, assay, automation, scale and local expertise.

Reading the table: Drug screening and toxicity testing here refer to laboratory studies, not clinical trials. Tissue transport measurements are not equivalent to validated whole-body pharmacokinetic predictions.

Organ-on-a-chip vs organoid-on-a-chip

Organ-on-a-chip uses living cells within an engineered device to mimic selected biological functions. Many designs use organised cell layers lining channels or membranes, but others contain three-dimensional tissues. Devices are often made from polymers and can provide controlled fluid flow and other physical cues.

Organoid-on-a-chip integrates a self-organised, three-dimensional organoid into a chip-based culture system. This combines the organoid’s tissue-like organisation with the device’s control of the surrounding environment, such as fluid flow, nutrient delivery and exposure to drugs.

An organoid-on-a-chip can be considered a type of organ-on-a-chip. Combining the approaches can offer complementary strengths, but improved performance must be demonstrated for the intended research question.

Related approach: organoid xenotransplants

Organoid xenotransplantation places human organoids into an animal host. Host vascular connections and systemic cues can support survival and maturation in some models, but they do not guarantee fully adult-like human tissue.

Potential uses: tissue maturation, graft integration, tumour behaviour and preclinical regenerative studies. Limitations: animal use, cross-species interactions, host immune context and graft safety. Immunodeficient hosts are common, but are not universal.

In a 2019 mouse kidney-capsule transplantation study, grafts remained immature and developed cartilage, cysts and stromal expansion during long-term observation. These are findings from that model, not universal outcomes of transplantation.

This is an animal-based hybrid approach. It should not be presented as a non-animal model.

Primary study: kidney organoid vascularisation in a chick embryo host ↗ · Primary study: mouse kidney-capsule graft immaturity and safety concerns ↗

Organoids from children: paediatric research & precision medicine

Organoids can be grown from cells or tissue samples donated by children. Depending on the model, researchers can use suitable tissue-derived cells or reprogramme sampled cells into iPSCs before differentiation. Successful culture depends on the tissue, cell source and protocol.

These models support paediatric disease research and drug testing, and researchers are evaluating how they can inform personalised treatment decisions. This is an active area of clinical translation; broad claims that organoids already transform routine paediatric treatment overstate the evidence.

Childhood inflammatory bowel disease

Cambridge researchers grew more than 300 intestinal organoid cultures using samples from 160 patients, mainly children and adolescents, to investigate inflammatory bowel disease biology. Samples included Crohn’s disease, ulcerative colitis and non-IBD controls; the research was published in Gut in June 2024.

Read the Cambridge research summary ↗

Childhood kidney cancers

A published paediatric kidney cancer organoid biobank captured features of several tumour types and provided models for biological studies and drug screening. Establishing a research biobank is different from demonstrating improved patient outcomes.

Read the primary study ↗
How well do organoids predict treatment response?

Evidence depends on the disease, drug and assay. In cystic fibrosis, organoid assays have helped investigate CFTR modulator responses. In a randomised ivacaftor study involving the CFTR mutations 3849+10kb C→T or D1152H, correlations between organoid swelling and clinical endpoints were negligible to low; swelling did not predict an individual’s clinical benefit in that trial. A response in culture therefore needs clinical interpretation.

Read the clinical study ↗

Choose the model that fits your question

Define the biology first

  1. Question: What mechanism or decision do you need to address?
  2. Cells: Which identities, donors and disease states matter?
  3. Environment: Do you need a barrier, flow, matrix, stretch or immune cells?
  4. Readout: What measurable function will answer the question?
  5. Evidence: What controls and reference data will demonstrate performance?

Match features to needs

Patient variation: consider donor-derived cultures or iPSC panels.

Flow or mechanical effects: consider chips or perfused systems.

Interactions between tissues: consider assembloids, co-cultures or linked platforms.

Screening scale: balance biological relevance with automation, cost and consistency.

What should good reporting include?

Cell source, identity and contamination testing; donor metadata where appropriate; culture and passage history; medium and matrix composition; device materials and geometry; flow and exposure conditions; viability and relevant functions; controls; independent donors or batches; and the statistical analysis.

Does human-derived mean animal-free?

No. Human cells can be cultured with animal-derived serum, matrix or other reagents. Check the whole workflow. “Serum-free”, “chemically defined”, “xeno-free” and “animal-free” describe different properties.

What does regulatory acceptance mean?

Acceptance concerns a particular method, endpoint and context of use, rather than an entire model family. The 2022 legislation commonly called the FDA Modernization Act 2.0 changed the statutory wording from animal or preclinical tests to nonclinical tests, expressly including cell-based assays, microphysiological systems and computer modelling. It removed the statutory requirement that these tests must be animal studies; it did not remove the need for adequate safety evidence or give blanket acceptance to every platform.

The FDA’s 2025 roadmap describes a staged approach to reducing animal testing in preclinical safety studies. On 22 September 2026, FDA published a direct final rule to update regulatory terminology to “nonclinical” testing. As of this guide’s review on 1 October 2026, that rule is not yet effective: its stated effective date is 4 February 2027, with comments due by 7 December 2026. The effective date is subject to the direct-final-rule comment process; significant adverse comments could result in withdrawal. The rule introduces no new requirements.

Non-animal evidence does not automatically replace every animal study or clinical trial. Check the current requirements for the intended application.

FDA 2025 roadmap ↗ · FDA September 2026 rule and statutory background ↗
Can these models replace animal studies?

They can replace or reduce animal use for specific questions when supported by suitable evidence. Acceptance depends on the application and relevant decision-making framework; a platform label alone does not establish suitability.

Your advanced cell model glossary

3D cell culture
Culture in which cells occupy a three-dimensional arrangement rather than a flat monolayer.
3Rs
Replacement, Reduction and Refinement: principles for replacing animal use, using fewer animals and minimising harm.
ADME
Absorption, distribution, metabolism and excretion: processes that determine what happens to a compound in the body.
Adult / tissue-resident stem cell
A stem cell that maintains or repairs a particular tissue. The term adult stem cell does not mean that the donor must be an adult.
Air–liquid interface (ALI)
Culture with the upper cell surface exposed to air and the lower surface supplied with medium; often used for airway epithelium.
Angiogenesis
Formation of new blood vessels from existing vessels.
Apical / basal
The surface facing a lumen or outside space (apical) and the surface facing the underlying matrix or support (basal).
Assay
A defined procedure for measuring a biological, chemical or physical property.
Assembloid
An integrated culture combining organoids with other organoids or specialised cells to model their interactions.
Barrier function
The ability of a cell layer or tissue to regulate passage of molecules, particles or cells.
Batch effect
Systematic differences associated with separate preparation, culture or measurement batches.
Bioink
A printable formulation containing cells and/or biomaterials used to build tissue constructs.
Bioprinting
Spatial deposition of cells and biomaterials using a controlled printing process.
Bioreactor
A culture system that controls environmental conditions such as mixing, nutrient supply or gas exchange.
Co-culture
Culture of two or more cell populations in the same experimental system.
Context of use
The specific question, decision and conditions for which a model or assay is intended.
Cryopreservation
Storage of biological material at very low temperatures using procedures designed to preserve viability.
Differentiation
The process by which cells acquire specialised identities and functions.
Donor variability
Biological differences between people or source organisms that can influence model behaviour.
Endothelium
The cell layer lining blood and lymphatic vessels.
Endpoint
The defined outcome measured in an experiment, such as viability, permeability or cytokine release.
Epithelium
A cell layer covering a surface or lining a cavity, often with transport, barrier or secretory roles.
Ex vivo
Studied outside the organism using tissue or cells removed from it.
Explant
A piece of tissue removed from an organism and maintained or studied outside it.
Extracellular matrix (ECM)
The network of proteins and other molecules surrounding cells that provides support and biochemical cues.
Fit for purpose
Suitable for a specified use based on relevant evidence; it does not mean suitable for every question.
Growth factor
A signalling molecule that can influence cell survival, proliferation, differentiation or other behaviours.
High-content imaging
Imaging-based measurement of multiple cellular or tissue features.
High-throughput screening
Testing many samples or conditions using parallelised and often automated methods.
Hydrogel
A water-rich polymer network used as a support or microenvironment in some cell cultures.
Immune-competent model
A model containing immune components with demonstrated functions relevant to the study.
In silico
Studied using computational methods or simulations.
In vitro
Studied outside an organism in a controlled experimental environment.
Induced pluripotent stem cell (iPSC)
A somatic cell reprogrammed to a pluripotent state, capable of generating cell types from the three embryonic germ layers.
Low-attachment culture
Culture using surfaces designed to discourage cell attachment, often promoting cell aggregation.
Lumen
An internal cavity, such as the space inside a gut organoid or vessel.
Matrigel
An animal-derived basement membrane extract widely used in culture; composition can vary between batches.
Maturation
Development of cell or tissue features toward a more functionally developed state; it must be assessed for the intended use.
Mechanobiology
The study of how physical forces and mechanical properties influence biological behaviour.
Microfluidics
Control of small fluid volumes in channels or structures with microscale dimensions.
Microphysiological system (MPS)
An in vitro platform designed to reproduce selected tissue or organ physiology; the breadth of the term varies.
Multi-organ system
A platform linking models of two or more tissues to study exchanges or interactions.
NAMs
New approach methodologies: approaches used to replace animal testing, especially in hazard and safety assessment; usage varies by sector.
Necrotic core
A central region of dead cells that can develop when oxygen and nutrient delivery or waste removal are insufficient.
Organ-on-a-chip (OoC)
An engineered culture device recreating selected organ functions using living cells and controlled microenvironmental cues.
Organoid
A self-organising 3D culture reproducing selected tissue architecture and function, derived from stem, progenitor or differentiated cells.
Organoid-on-a-chip
A culture system integrating an organoid into an engineered chip environment, often to control flow, nutrient delivery or experimental exposure.
Organotypic culture
A culture that maintains or recreates selected features of tissue organisation and function.
Passage
Transfer or subdivision of a culture to sustain or expand it; passage number records these events.
Patient-derived organoid (PDO)
An organoid culture established from patient tissue, including healthy or diseased tissue.
Perfusion
Movement of culture medium through or around a model to deliver substances and remove waste.
Pharmacokinetics
The study of how drug concentrations change over time through absorption, distribution, metabolism and excretion.
Phenotype
Observable properties of cells or tissues, including morphology, molecular markers and function.
Pluripotency
The ability of a stem cell to generate cell types from all three embryonic germ layers.
Polarity
Organised differences between cell surfaces or regions, important for directional transport and tissue function.
Precision medicine
An approach that uses relevant individual characteristics, such as molecular features or functional responses, to inform prevention, diagnosis or treatment.
Reproducibility
The ability to obtain consistent findings under specified conditions; report how consistency was assessed.
Scaffold
A material or structure that supports cell attachment and tissue organisation.
Self-organisation
Emergence of organised structures through interactions between cells and their environment.
Shear stress
Tangential force per unit area exerted by flowing fluid on a surface such as a cell layer.
Spheroid
A 3D cell aggregate with an approximately rounded form; it need not have organ-specific organisation.
Stem cell
A cell capable of self-renewal and of producing differentiated progeny.
TEER
Transepithelial/transendothelial electrical resistance: an electrical measure used to assess barrier properties.
Transwell
A culture insert with a porous membrane separating upper and lower compartments.
Tumoroid
A tumour-derived organoid model. Terminology varies; describe its source, composition and retained tumour features.
Tumour microenvironment
The non-malignant cells, matrix, signals and physical conditions surrounding and interacting with tumour cells.
Validation
Evaluation of whether a method reliably measures or predicts the outcomes required for a stated use.
Vascularisation
Formation or incorporation of vessel structures; functional perfusion requires additional evidence.
Vascularised organoid
An organoid containing or integrated with vascular structures; functional perfusion must be demonstrated separately.
Xeno-free
Prepared without components from another species; this does not necessarily mean free of all animal-derived components.
Xenotransplantation
Transplantation across species, such as placing human organoids into an animal host.

Sources & further exploration